NCT00013806Unknown2 期
CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study
National Center for Research Resources (NCRR)1 个研究点 分布在 1 个国家开始时间: 2001年3月30日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 试验地点
- 1
研究概览
简要总结
131I-metaiodobenzylguanidine (131I-MIBG) is a norepinephrine analog that concentrates in adrenergic tissue and therefore holds promise for cell-specific treatment of neuroblastoma. This is a dual institution, Phase II study of 131I-MIBG administered at the previously defined maximum practical dose of 18 mCi/kg to children with relapsed or refractory neuroblastoma.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 0 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Refractory neuroblastoma with original diagnosis based on tumor histopathology or elevated urine VMA with typical tumor cells in the bone marrow.
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
I-131 MIBG(I-131 Meta-Iodobenzylguanidine) radiotherapy for malignant neuroendocrine tumorsmalignant neuroendocrine tumorsJPRN-UMIN000017057Kagoshima university hospital Department of Radiology25
Available
不适用
131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access ProtocolChildhood Metastatic PheochromocytomaNeuroblastomaNCT01163383John Maris
已完成
3 期
High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine TumorsNeuroendocrine TumorsMetastases, NeoplasmNCT00037869M.D. Anderson Cancer Center15
已完成
不适用
MIBG for Refractory Neuroblastoma and PheochromocytomaMetastatic PheochromocytomaRelapsed NeuroblastomaNCT01850888Masonic Cancer Center, University of Minnesota15
已完成
2 期
A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related TumorsParagangliomaPheochromocytomaNCT01413503University of California, San Francisco50